OC METRO CALENDAR

  • January 2015
    SuMoTuWeThFrSa
    28293031123
    45678910
    11121314151617
    18192021222324
    25262728293031
    1234567
Add an event

PHARMACEUTICALS
Untitled Page Published: March 16, 2009 09:55 AM




Spectrum Pharmaceuticals' acquisition continued ...

Zevalin is an FDA-approved drug for patients with relapsed or refractory, low-grade or follicular B-cell Non-Hodgkin's Lymphoma. Zevalin is currently under review by the FDA for use as a first-line consolidation therapy, which aims to rapidly improve the quality of response achieved from initial treatments that reduce the number of cancer cells in the body.

If approved, Zevalin will be the first treatment available to patients as a first-line consolidation therapy to treat Non-Hodgkin's Lymphoma. The drug's current patient population would increase by 18,000, and it could be used in several different lines of treatment. A decision is expected in July.

Spectrum Pharmaceuticals is a biopharmaceutical company that acquires, develops and commercializes drug products with a focus on oncology and urology.


PAGE ONE

Related headlines
San Clemente's STEMTech to Obama: What about adult stem cells?
Test results in: Clarient of Aliso Viejo's revenues soar
"OC METRO Minute," March 13: UCI's geriatrics program receives funding from Donald W. Reynolds Foundation
"OC METRO Minute," March 11: Epinex's diabetes monitoring device